What do I need to know about Rhenium-SCT® (skin cancer therapy)?1-5
Rhenium-SCT® (Skin Cancer Therapy) is a brachytherapy utilising the Beta emitter radioisotope Rhenium-188 for the treatment Non-Melanoma Skin Cancer.
Rhenium-SCT® is approved in Europe, South Africa and Australia for the treatment of basal and squamous cell carcinomas of the skin.
In general, Rhenium-SCT® can be applied to any location on the body. It can be applied to single and/or multiple lesions of almost any shape or size in just one session. It is also suitable for patients of any age as well as patients with previously treated or complicated lesions.
The Rhenium-SCT® is not recommended for minors or pregnant patients.
**Accurate dosing. Spares healthy tissue.
‡No reported pain
†A procedure is considered non-invasive when no break or cut in the skin is created.
*Complete tumour regression in 98.5% of lesions treated3
§No disfiguring scarring; Retained functionality in high-risk and difficult to treat areas.
Rhenium-SCT demonstration video
Fees and charges
SBG is a licenced provider of radioisotope therapy, and along with VMOs, provides dermal brachytherapy services for Non-Melanoma Skin Cancers (NMSC). Fees charged by all VMOs are set independently and are generally below Australian Medical Association (AMA) rates. However, due to the technical and manufacturing expertise required to produce radioisotopes, the cost of treating a single small lesion in the vicinity of a critical structure, such as face, eyes, nose or ears, should be quoted at around $7,000 to $8,000 (AUD). The inclusion of this treatment as a rebateable item in Medicare and private health funds has not yet been finalised, and as such there is currently no rebate. This means that a single treatment will be of $7,000 to $8,000 (AUD).
SBG, as an accredited radioisotope facility, can provide services to the VMOs on a similar basis as a surgeon is provided services at a hospital grade facility.